Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Freeman

Showing results (321-330 of 386) with videos related to

Pageof 39
Sort By:
Genetic Epidemiology|January 1, 1990
Blood pressure and other cardiovascular disease risk factors in black adults with sickle cell trait or glucose-6-phosphate dehydrogenase deficiencyM U Nwankwo, C H Bunker, F A Ukoli, et al.
Comparative Medicine|November 19, 2021
Elucidation of the Central Serotonin Metabolism Pathway in Rhesus Macaques (<i>Macaca mulatta</i>) with Self-injurious BehaviorRachael L Cohen, Julia L Drewes, Suzanne E Queen, et al.
Toxicologic Pathology|January 1, 2019
The Endothelin-A Receptor Antagonist Zibotentan Induces Damage to the Nasal Olfactory Epithelium Possibly Mediated in Part through Type 2 Innate Lymphoid CellsMarian A Esvelt, Zachary T Freeman, Alexander T Pearson, et al.
Plos One|December 4, 2024
Consistency and flexibility of character in free-ranging male African elephants across time, age, and social contextsCaitlin E O'Connell-Rodwell, Jodie L Berezin, Colleen Kinzley, et al.
The New Zealand Medical Journal|October 16, 2013
Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCR-ribotype 244Mary N De Almeida, Helen Heffernan, Anne Dervan, et al.
ACS Chemical Neuroscience|January 28, 2017
A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH<sub>2</sub> versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH<sub>2</sub>: A Bivalent AdvantageCody J Lensing, Danielle N Adank, Stacey L Wilber, et al.
Journal of Geriatric Oncology|January 16, 2020
Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumabDoran Ksienski, Elaine S Wai, Nicole S Croteau, et al.
Cancers|July 24, 2021
Stakeholder Perceptions of Key Aspects of High-Quality Cancer Care to Assess with Patient Reported Outcome Measures: A Systematic ReviewAngela M Stover, Rachel Kurtzman, Jennifer Walker Bissram, et al.
The Journal of Investigative Dermatology|February 20, 2021
Development of hMC1R Selective Small Agonists for Sunless Tanning and Prevention of Genotoxicity of UV in MelanocytesLeonid Koikov, Renny J Starner, Viki B Swope, et al.
Journal of Medicinal Chemistry|June 12, 2023
Discovery of a Pan-Melanocortin Receptor Antagonist [Ac-DPhe(pI)-Arg-Nal(2')-Orn-NH<sub>2</sub>] at the MC1R, MC3R, MC4R, and MC5R that Mediates an Increased Feeding Response in Mice and a 40-Fold Selective MC1R Antagonist [Ac-DPhe(pI)-DArg-Nal(2')-Arg-NH<sub>2</sub>]Mark D Ericson, Linh T Tran, Sarah S Mathre, et al.
Pageof 39

Showing results (321-330 of 386) with videos related to

Sort By:
Pageof 39
Genetic Epidemiology|January 1, 1990
Blood pressure and other cardiovascular disease risk factors in black adults with sickle cell trait or glucose-6-phosphate dehydrogenase deficiencyM U Nwankwo, C H Bunker, F A Ukoli, et al.
Comparative Medicine|November 19, 2021
Elucidation of the Central Serotonin Metabolism Pathway in Rhesus Macaques (<i>Macaca mulatta</i>) with Self-injurious BehaviorRachael L Cohen, Julia L Drewes, Suzanne E Queen, et al.
Toxicologic Pathology|January 1, 2019
The Endothelin-A Receptor Antagonist Zibotentan Induces Damage to the Nasal Olfactory Epithelium Possibly Mediated in Part through Type 2 Innate Lymphoid CellsMarian A Esvelt, Zachary T Freeman, Alexander T Pearson, et al.
Plos One|December 4, 2024
Consistency and flexibility of character in free-ranging male African elephants across time, age, and social contextsCaitlin E O'Connell-Rodwell, Jodie L Berezin, Colleen Kinzley, et al.
The New Zealand Medical Journal|October 16, 2013
Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCR-ribotype 244Mary N De Almeida, Helen Heffernan, Anne Dervan, et al.
ACS Chemical Neuroscience|January 28, 2017
A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH<sub>2</sub> versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH<sub>2</sub>: A Bivalent AdvantageCody J Lensing, Danielle N Adank, Stacey L Wilber, et al.
Journal of Geriatric Oncology|January 16, 2020
Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumabDoran Ksienski, Elaine S Wai, Nicole S Croteau, et al.
Cancers|July 24, 2021
Stakeholder Perceptions of Key Aspects of High-Quality Cancer Care to Assess with Patient Reported Outcome Measures: A Systematic ReviewAngela M Stover, Rachel Kurtzman, Jennifer Walker Bissram, et al.
The Journal of Investigative Dermatology|February 20, 2021
Development of hMC1R Selective Small Agonists for Sunless Tanning and Prevention of Genotoxicity of UV in MelanocytesLeonid Koikov, Renny J Starner, Viki B Swope, et al.
Journal of Medicinal Chemistry|June 12, 2023
Discovery of a Pan-Melanocortin Receptor Antagonist [Ac-DPhe(pI)-Arg-Nal(2')-Orn-NH<sub>2</sub>] at the MC1R, MC3R, MC4R, and MC5R that Mediates an Increased Feeding Response in Mice and a 40-Fold Selective MC1R Antagonist [Ac-DPhe(pI)-DArg-Nal(2')-Arg-NH<sub>2</sub>]Mark D Ericson, Linh T Tran, Sarah S Mathre, et al.
Pageof 39